AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04891848 — intervention group
Intervention type: OTHER
Intervention: inflammation
Description: inflammatory values in complete blood count (CBC)
Study NCT03670810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.
Study NCT03670810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lasmiditan
Description: Administered orally.
Study NCT03670810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT03670810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT03405142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is \< 1/12 of the therapeutic dose.
Study NCT03405142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek
Description: Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
Study NCT02995252 — intervention group
Intervention type: OTHER
Intervention: Blood draws
Study NCT02995252 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Alafenamide
Description: 25 mg tablet, once a day by mouth.
Study NCT02995252 — intervention group
Intervention type: OTHER
Intervention: Knowledge Index Questionnaire
Study NCT02995252 — intervention group
Intervention type: OTHER
Intervention: Liver transient elastography (FibroScan)
Description: Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
Study NCT02995252 — intervention group
Intervention type: PROCEDURE
Intervention: Liver Biopsy
Description: 40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
Study NCT04117126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prompted voiding
Description: Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control.
Study NCT01299831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 72 hour fast
Description: The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
Study NCT01299831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control, 12 hour fast
Description: The 12 hour fast will be used as a basic metabolic control
Study NCT01299831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
Study NCT01299831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olbetam
Description: The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours.
Study NCT03890731 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BAY73-4506 (Regorafenib, Stivarga)
Description: Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
Study NCT03441828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality of surgical field conditions
Description: evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
Study NCT01434524 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: LIVACT
Description: LIVACT contains 13.0 g of free amino acids
Study NCT01820416 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy
Description: Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
Study NCT01820416 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Disabled Laser
Description: Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
Study NCT04355000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hall technique
Description: SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
Study NCT04355000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RMGIC restoration
Description: Complete removal of caries and filling will be done with RMGIC material
Study NCT04364529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The pit crew model
Description: The pit crew model
Study NCT00097721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: The first cohort of subjects were to receive E7389 1.4 mg/m\^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m\^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
Study NCT00215046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: drug - dosage and frequency is based on size of patient and response to treatment.
Study NCT00215046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
Study NCT03352921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical pilates exercises
Description: servikal, deep flexor muscles, posture exercsises
Study NCT03352921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercises program
Description: stretching, strengthening, and posture exercises to reduce functional disability, to relieve the pain and to provide postural straightening.
Study NCT01352494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles
Study NCT01352494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
Study NCT00499096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic care model for Bipolar Disorder
Description: The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
Study NCT02737124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be given 24 hours before scheduled surgery.
Study NCT03441828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality of surgical field conditions
Description: evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
Study NCT03441828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep Neuromuscular Block
Description: maintenance of a deep neuromuscular block by infusion of rocuronium
Study NCT03441828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Neuromuscular Block
Description: maintenance of a moderate neuromuscular block.
Study NCT01388322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 40 mg (4000 IU) women \<80 kg at the time of randomization or 60 mg (6000 IU) women> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
Study NCT02961361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
Study NCT02737124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to subjects 24 hours before scheduled surgery.
Study NCT04344236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Povidone/Iodine oral/nasal rinse
Description: 5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
Study NCT04344236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine oral/nasal rinse
Description: 5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
Study NCT02801565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional controlled ovarian stimulation proctol
Description: Conventional controlled ovarian stimulation proctol without rhGH.
Study NCT02961361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine mixed with dexmedetomidine
Description: 40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
Study NCT01629121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education intervention
Description: The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated.
Study NCT05149716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine
Description: Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day
Study NCT01727804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser in caries prevention
Study NCT04647773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 20mg BID
Description: HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
Study NCT04647773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 40mg BID
Description: HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
Study NCT04647773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 60mg BID
Description: HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
Study NCT04647773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 80mg BID
Description: HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
Study NCT04647773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg BID
Description: Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
Study NCT04647773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID
Description: Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
Study NCT05149716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day
Study NCT03950947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplatzer vascular plug
Description: See above
Study NCT03950947 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Controll
Description: Angiography of the RIMA without occlusion
Study NCT01714726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI2070
Description: 1 iv infusion on Week 0 and Week 4
Study NCT01714726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 iv infusion on Week 0 and Week 4
Study NCT01768169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: fish oil capsule
Description: 500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
Study NCT02022566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A supported self management of osteoarthritis program
Description: Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
Study NCT01225458 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: shorter tests
Description: Geriatric evaluation with MMS, GDS and ADL scoring
Study NCT01225458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shorter tests
Description: Geriatric evaluation with MMS, GDS and ADL scoring
Study NCT01225458 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: initial complete geriatric tests
Description: evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
Study NCT01225458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: initial complete geriatric tests
Description: evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
Study NCT01225458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow-up complete geriatric tests
Description: evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
Study NCT00620191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg twice a day titrated from 500 mg once a day
Study NCT00620191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
Study NCT04435652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604
Description: 3mg/kg, D1,8,15,Q4w, IV infusion
Study NCT04435652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100mg/m2, D1,8,15,Q4w, IV infusion
Study NCT04435652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2, D1,8,15,Q4w, IV infusion
Study NCT04208061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Participants will receive single dose of dabigatran etexilate orally.
Study NCT03210961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 tablet
Description: PF-06826647 tablet for oral administration
Study NCT03210961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 oral suspension
Description: PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)
Study NCT03210961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution/suspension
Description: placebo oral solution for the single ascending dose, first cohort only
Study NCT03210961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Matching placebo tablet
Study NCT03956212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 7 days
Description: Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
Study NCT03956212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 14 days
Description: Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
Study NCT01695434 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: All subjects will undergo a MRI.
Study NCT04208061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/COBI
Description: Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).
Study NCT04208061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive ritonavir orally.
Study NCT04208061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants will receive Darunavir orally.
Study NCT01890876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking uphill
Description: ascending about 500 m
Study NCT01890876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking downhill
Description: descending about 500 m
Study NCT03598712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression by chest bandage urgo K2®
Description: 1. - Installation of a short stretch belt (urgo K2® kit)~2. - Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).~3. - Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device
Study NCT03598712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: punctures
Description: Every 7 days after the second puncture of a volume > 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
Study NCT02008344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: favipiravir
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily
Study NCT02008344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily
Study NCT02509845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: Antimicrobial peptide
Study NCT03598712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: punctures
Description: Every 7 days after the second puncture of a volume > 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
Study NCT00338377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Immunization
Description: 1x10\^7 to 2.5x10\^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
Study NCT00338377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
Study NCT00338377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
Study NCT00338377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cells
Description: On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.
Study NCT00338377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
Study NCT00338377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
Study NCT00338377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrathecal T-Cells
Description: 5.0x10\^9 T-cells administered on Day 1, and 10x10\^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.